{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T04:10:05Z","timestamp":1751688605616,"version":"3.41.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Administration of human therapeutic proteins such as monoclonal antibodies (mAb) to animals during preclinical drug development often leads to the development of anti-drug antibodies (ADA). ADA may reduce the systemic exposure of the mAb by enhancing its immune-complex mediated clearance. Thus, ADA may hinder the preclinical pharmacokinetic and toxicology assessments of mAbs. To mitigate this effect, we explored the ability of short-term administration of immunosuppressants to induce prolonged immune tolerance towards a human mAb, erenumab, in rats. In two studies, we investigated dosing regimens using the immunosuppressants methotrexate and tacrolimus\/sirolimus combination, and compared them to non-immunosuppressed control groups. Each study comprised three phases: induction (weeks 1\u20134), washout (weeks 5\u20138), and rechallenge (weeks 9\u201312). Animals received mAb during the induction and rechallenge phase, while immunosuppression was limited to the induction and washout phase. Blood samples were collected at predefined time-points for erenumab and ADA quantification. The tacrolimus\/sirolimus regimen, but not the tested methotrexate regimens, completely prevented ADA formation in all treated animals relative to the control groups. The tacrolimus\/sirolimus treated animals not only remained ADA-negative with initial immunosuppression during the induction phase but remained ADA-negative even after erenumab rechallenge suggesting the induction of immune-tolerance beyond the immunosuppressive treatment period. Correspondingly, erenumab systemic exposures were maintained throughout the study period in all animals in the tacrolimus\/sirolimus group and were similar to the erenumab exposures in ADA-negative animals of the control group. In contrast, ADA-positive animals in the control group exhibited a 60\u201380% reduction in erenumab exposures.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical Abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1208\/s12248-025-01083-0","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T22:05:54Z","timestamp":1747433154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Short-Term Immunosuppression in Rats Induces Prolonged Immune Tolerance Towards a Human Monoclonal Antibody, Erenumab"],"prefix":"10.1208","volume":"27","author":[{"given":"Paridhi","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josiah T.","family":"Ryman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kozhich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vibha","family":"Jawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3923-3648","authenticated-orcid":false,"given":"Bernd","family":"Meibohm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"issue":"2","key":"1083_CR1","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","volume":"14","author":"N Chirmule","year":"2012","unstructured":"Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy. AAPS J. 2012;14(2):296\u2013302.","journal-title":"AAPS J"},{"issue":"2","key":"1083_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1208\/s12248-016-0026-8","volume":"19","author":"J Herskovitz","year":"2017","unstructured":"Herskovitz J, Ryman J, Thway T, Lee S, Zhou L, Chirmule N, et al. Immune suppression during preclinical drug development mitigates immunogenicity-mediated impact on therapeutic exposure. AAPS J. 2017;19(2):447\u201355.","journal-title":"AAPS J"},{"issue":"9","key":"1083_CR3","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576\u201388.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"10","key":"1083_CR4","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.4049\/jimmunol.1202017","volume":"189","author":"LP Ganesan","year":"2012","unstructured":"Ganesan LP, Kim J, Wu Y, Mohanty S, Phillips GS, Birmingham DJ, et al. FcgammaRIIb on liver sinusoidal endothelium clears small immune complexes. J Immunol. 2012;189(10):4981\u20138.","journal-title":"J Immunol"},{"issue":"4","key":"1083_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40259-016-0181-6","volume":"30","author":"DR Mould","year":"2016","unstructured":"Mould DR, Meibohm B. Drug development of therapeutic monoclonal antibodies. BioDrugs. 2016;30(4):275\u201393.","journal-title":"BioDrugs"},{"key":"1083_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2015.01.003","volume":"417","author":"C Kloks","year":"2015","unstructured":"Kloks C, Berger C, Cortez P, Dean Y, Heinrich J, Bjerring Jensen L, et al. A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective. J Immunol Methods. 2015;417:1\u20139.","journal-title":"J Immunol Methods"},{"issue":"2","key":"1083_CR7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.cellimm.2015.03.002","volume":"295","author":"L Yin","year":"2015","unstructured":"Yin L, Chen X, Vicini P, Rup B, Hickling TP. Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products. Cell Immunol. 2015;295(2):118\u201326.","journal-title":"Cell Immunol"},{"issue":"5","key":"1083_CR8","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.xphs.2016.02.031","volume":"105","author":"W Jiskoot","year":"2016","unstructured":"Jiskoot W, Kijanka G, Randolph TW, Carpenter JF, Koulov AV, Mahler HC, et al. Mouse models for assessing protein immunogenicity: lessons and challenges. J Pharm Sci. 2016;105(5):1567\u201375.","journal-title":"J Pharm Sci"},{"issue":"13","key":"1083_CR9","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1182\/blood-2010-11-316521","volume":"118","author":"PM van Helden","year":"2011","unstructured":"van Helden PM, Unterthurner S, Hermann C, Schuster M, Ahmad RU, Schiviz AN, et al. Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model. Blood. 2011;118(13):3698\u2013707.","journal-title":"Blood"},{"key":"1083_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jim.2014.02.011","volume":"410","author":"MA Brehm","year":"2014","unstructured":"Brehm MA, Wiles MV, Greiner DL, Shultz LD. Generation of improved humanized mouse models for human infectious diseases. J Immunol Methods. 2014;410:3\u201317.","journal-title":"J Immunol Methods"},{"issue":"1","key":"1083_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1365-2249.2008.03602.x","volume":"152","author":"A Joseph","year":"2008","unstructured":"Joseph A, Munroe K, Housman M, Garman R, Richards S. Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin Exp Immunol. 2008;152(1):138\u201346.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"1083_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/gim.2011.4","volume":"14","author":"YH Messinger","year":"2012","unstructured":"Messinger YH, Mendelsohn NJ, Rhead W, Dimmock D, Hershkovitz E, Champion M, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med. 2012;14(1):135\u201342.","journal-title":"Genet Med"},{"issue":"9","key":"1083_CR13","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41(9):1552\u201363.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1083_CR14","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1097\/00007890-199712270-00039","volume":"64","author":"MD Vu","year":"1997","unstructured":"Vu MD, Qi S, Xu D, Wu J, Fitzsimmons WE, Sehgal SN, et al. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation. 1997;64(12):1853\u20136.","journal-title":"Transplantation"},{"issue":"7","key":"1083_CR15","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1097\/00007890-200004150-00012","volume":"69","author":"S Qi","year":"2000","unstructured":"Qi S, Xu D, Peng J, Vu MD, Wu J, Bekersky I, et al. Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey. Transplantation. 2000;69(7):1275\u201383.","journal-title":"Transplantation"},{"key":"1083_CR16","unstructured":"Animal Welfare Act and animal welfare regulations; 9 CFR Parts 1, 2, and 3. Vol. 54. 2005, Washington, D.C.: U.S. Dept. of Agriculture."},{"issue":"1","key":"1083_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/ilar.38.1.41","volume":"38","author":"JD Clark","year":"1997","unstructured":"Clark JD, Gebhart GF, Gonder JC, Keeling ME, Kohn DF. Special report: the 1996 guide for the care and use of laboratory animals. ILAR J. 1997;38(1):41\u20138.","journal-title":"ILAR J"},{"issue":"4","key":"1083_CR18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00007890-199802270-00004","volume":"65","author":"DA Hale","year":"1998","unstructured":"Hale DA, Gottschalk R, Maki T, Monaco AP. Determination of an improved sirolimus (rapamycin)-based regimen for induction of allograft tolerance in mice treated with antilymphocyte serum and donor-specific bone marrow. Transplantation. 1998;65(4):473\u20139.","journal-title":"Transplantation"},{"issue":"4","key":"1083_CR19","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s11095-024-03678-2","volume":"41","author":"JR Cohen","year":"2024","unstructured":"Cohen JR, Brych SR, Prabhu S, Bi V, Elbaradei A, Tokuda JM, et al. A high threshold of biotherapeutic aggregate numbers is needed to induce an immunogenic response in vitro, in vivo, and in the clinic. Pharm Res. 2024;41(4):651\u201372.","journal-title":"Pharm Res"},{"key":"1083_CR20","doi-asserted-by":"publisher","first-page":"915412","DOI":"10.3389\/fimmu.2022.915412","volume":"13","author":"MD Swanson","year":"2022","unstructured":"Swanson MD, Rios S, Mittal S, Soder G, Jawa V. Immunogenicity risk assessment of spontaneously occurring therapeutic monoclonal antibody aggregates. Front Immunol. 2022;13:915412.","journal-title":"Front Immunol"},{"issue":"2","key":"1083_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.xphs.2015.11.002","volume":"105","author":"EM Moussa","year":"2016","unstructured":"Moussa EM, Panchal JP, Moorthy BS, Blum JS, Joubert MK, Narhi LO, et al. Immunogenicity of therapeutic protein aggregates. J Pharm Sci. 2016;105(2):417\u201330.","journal-title":"J Pharm Sci"},{"issue":"11","key":"1083_CR22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s11095-019-2690-8","volume":"36","author":"R Bansal","year":"2019","unstructured":"Bansal R, Gupta S, Rathore AS. Analytical platform for monitoring aggregation of monoclonal antibody therapeutics. Pharm Res. 2019;36(11):152.","journal-title":"Pharm Res"},{"issue":"1\u20132","key":"1083_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ijpharm.2006.08.024","volume":"329","author":"B Demeule","year":"2007","unstructured":"Demeule B, Gurny R, Arvinte T. Detection and characterization of protein aggregates by fluorescence microscopy. Int J Pharm. 2007;329(1\u20132):37\u201345.","journal-title":"Int J Pharm"},{"issue":"2","key":"1083_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/cei.12742","volume":"184","author":"GR Gunn 3rd","year":"2016","unstructured":"Gunn GR 3rd, Sealey DC, Jamali F, Meibohm B, Ghosh S, Shankar G. From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals. Clin Exp Immunol. 2016;184(2):137\u201346.","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"1083_CR25","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1208\/s12248-014-9599-2","volume":"16","author":"G Shankar","year":"2014","unstructured":"Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J. 2014;16(4):658\u201373.","journal-title":"AAPS J"},{"issue":"3","key":"1083_CR26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/rheumatology\/kem279","volume":"47","author":"JA Wessels","year":"2008","unstructured":"Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2008;47(3):249\u201355.","journal-title":"Rheumatology (Oxford)"},{"issue":"1 Pt A","key":"1083_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.imlet.2014.07.006","volume":"162","author":"J Shan","year":"2014","unstructured":"Shan J, Feng L, Li Y, Sun G, Chen X, Chen P. The effects of rapamycin on regulatory T cells: its potential time-dependent role in inducing transplant tolerance. Immunol Lett. 2014;162(1 Pt A):74\u201386.","journal-title":"Immunol Lett."},{"key":"1083_CR28","doi-asserted-by":"publisher","first-page":"172872","DOI":"10.1016\/j.ejphar.2019.172872","volume":"869","author":"J Song","year":"2020","unstructured":"Song J, Du G, Chen W, Bao P, Li B, Lu Q, et al. The advantage of Sirolimus in amplifying regulatory B cells and regulatory T cells in liver transplant patients. Eur J Pharmacol. 2020;869:172872.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"1083_CR29","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.intimp.2009.01.033","volume":"9","author":"A Ma","year":"2009","unstructured":"Ma A, Qi S, Wang Z, Massicotte E, Dupuis M, Daloze P, et al. Combined therapy of CD4(+)CD25(+) regulatory T cells with low-dose sirolimus, but not calcineurin inhibitors, preserves suppressive function of regulatory T cells and prolongs allograft survival in mice. Int Immunopharmacol. 2009;9(5):553\u201363.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1083_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1182\/blood.V68.1.119.119","volume":"68","author":"R Storb","year":"1986","unstructured":"Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P, et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood. 1986;68(1):119\u201325.","journal-title":"Blood"},{"issue":"1","key":"1083_CR31","first-page":"1","volume":"21","author":"JM Kremer","year":"1994","unstructured":"Kremer JM. The mechanism of action of methotrexate in rheumatoid arthritis: the search continues. J Rheumatol. 1994;21(1):1\u20135.","journal-title":"J Rheumatol"},{"issue":"3","key":"1083_CR32","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/00007691-200206000-00004","volume":"24","author":"VC McAlister","year":"2002","unstructured":"McAlister VC, Mahalati K, Peltekian KM, Fraser A, MacDonald AS. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit. 2002;24(3):346\u201350.","journal-title":"Ther Drug Monit"},{"issue":"8","key":"1083_CR33","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1053\/jlts.2001.26510","volume":"7","author":"VC McAlister","year":"2001","unstructured":"McAlister VC, Peltekian KM, Malatjalian DA, Colohan S, MacDonald S, Bitter-Suermann H, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl. 2001;7(8):701\u20138.","journal-title":"Liver Transpl"},{"issue":"4","key":"1083_CR34","first-page":"411","volume":"8","author":"CE Biro","year":"1965","unstructured":"Biro CE, Garcia G. The antigenicity of aggregated and aggregate-free human gamma-globulin for rabbits. Immunology. 1965;8(4):411\u20139.","journal-title":"Immunology"},{"issue":"1","key":"1083_CR35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1084\/jem.115.1.253","volume":"115","author":"RT McCluskey","year":"1962","unstructured":"McCluskey RT, Miller F, Benacerraf B. Sensitization to denatured autologous gamma globulin. J Exp Med. 1962;115(1):253\u201373.","journal-title":"J Exp Med"},{"issue":"5","key":"1083_CR36","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/jps.20599","volume":"95","author":"S Hermeling","year":"2006","unstructured":"Hermeling S, Schellekens H, Maas C, Gebbink MF, Crommelin DJ, Jiskoot W. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci. 2006;95(5):1084\u201396.","journal-title":"J Pharm Sci"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01083-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01083-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01083-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T13:51:46Z","timestamp":1751637106000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01083-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["1083"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01083-0","relation":{},"ISSN":["1550-7416"],"issn-type":[{"type":"electronic","value":"1550-7416"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"23 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Paridhi Gupta, Ashish Srivastava and Bernd Meibohm have no conflict of interest to declare. Michael Swanson and Josiah T. Ryman do not have any relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or material discussed in the manuscript. Vibha Jawa and Alexander Kozhich are employees of Bristol Myers Squibb and own Bristol Myers Squibb stock.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"94"}}